A class action lawsuit has been initiated against Mereo BioPharma Group plc, with investors alleging the company issued materially false and misleading statements regarding its Phase 3 clinical development programs. The complaint centers on the ORBIT and COSMIC trials, which failed to achieve their respective primary endpoints, raising questions about the adequacy and timeliness of the company's public disclosures regarding these critical programs.
The lawsuit applies to investors who acquired Mereo securities during the period spanning June 5, 2023 through December 26, 2025. The case seeks to address potential losses sustained by shareholders during this window, when the clinical trial outcomes were not fully disclosed to the market.
Interested parties have until April 6, 2026 to seek lead plaintiff status in the proceeding. Class action investors are encouraged to contact legal counsel to understand their rights and potential eligibility to participate in the litigation.